Nutriband CEO to Present at 2026 Georgia Life Sciences Summit, Highlighting AVERSA Abuse-Deterrent Technology

Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and co-founder, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit. The summit, scheduled for Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, will bring together leaders from biotechnology, medical technology, research, manufacturing, and investment sectors. Sheridan will participate in the CEO Spotlight event on Aug. 26, providing a platform to discuss the company's innovative approach to addressing opioid abuse.

The core of Nutriband's presentation will likely center on AVERSA™, its abuse-deterrent transdermal technology. This technology is designed to incorporate aversive agents into transdermal patches, which can help prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The lead product under development is an abuse-deterrent fentanyl patch that leverages this technology. Fentanyl is a potent synthetic opioid, and its abuse has been a significant contributor to the opioid crisis. By making it harder to abuse fentanyl patches, Nutriband aims to reduce the risks associated with these powerful painkillers.

The significance of this presentation lies in the ongoing public health challenge posed by opioid abuse. According to the Centers for Disease Control and Prevention, opioid-related overdoses claim tens of thousands of lives annually in the United States. Abuse-deterrent formulations are seen as a crucial tool in mitigating this crisis. Nutriband's AVERSA technology could offer a new layer of protection by discouraging misuse through the addition of aversive agents that produce unpleasant effects if the drug is tampered with or taken inappropriately.

The summit provides a valuable opportunity for Nutriband to engage with key stakeholders in the life sciences industry. It allows the company to showcase its technology to potential partners, investors, and collaborators who are interested in addressing the opioid epidemic. The CEO Spotlight event is particularly notable as it gives a platform to emerging companies with innovative solutions.

Investors and industry observers will be watching closely to see how Nutriband positions its technology in the competitive landscape. The company's focus on transdermal delivery systems is part of a broader trend toward developing safer and more controlled methods of drug administration. If successful, the AVERSA technology could be incorporated into various transdermal patches, expanding its impact beyond fentanyl.

For more information about the summit and Nutriband's participation, interested parties can view the full press release at https://ibn.fm/Un3ax. Additionally, the company's newsroom provides updates on its latest developments at https://ibn.fm/NTRB.